Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5804157 | 0.84 | TDP1 (0.41) | TDP1ALDH1A1TSHRLMNAKDM4E | |
| SCHEMBL13871569 | 0.82 | RAB9A (0.42) | TDP1ALDH1A1TSHRCES2CES1 | |
| SCHEMBL6037494 | 0.82 | NPSR1 (0.41) | ALOX5TDP1ALDH1A1TSHRKDM4E | |
| SCHEMBL2895073 | 0.78 | CA1 (0.31) | — | |
| SCHEMBL25160105 | 0.76 | ALOX5 (0.43) | ALOX5ALDH1A1TSHRLMNAKDM4E | |
| SCHEMBL1954828 | 0.74 | ALOX5 (0.47) | ALOX5TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL6037553 | 0.73 | ALDH1A1 (0.46) | ALOX5TDP1ALDH1A1LMNAKDM4E | |
| SCHEMBL16937417 | 0.72 | ALDH1A1 (0.50) | ALOX5ALDH1A1TSHRLMNACES2 | |
| SCHEMBL3282167 | 0.72 | RAB9A (0.52) | ALOX5TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL11030370 | 0.72 | ALOX5 (0.46) | ALOX5TDP1ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | ALOX5 124/4885TDP1 3364/4885ALDH1A1 450/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | ALOX5 124/4885TDP1 3364/4885ALDH1A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.